An investigation on behalf of current long term investors in Roka Bioscience Inc (NASDAQ:ROKA) shares over possible breaches of fiduciary duty by certain officers and directors was announced and:ROKA stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/10/2015 -- An investigation on behalf of current long-term investors in shares of Roka Bioscience Inc (NASDAQ:ROKA concerning potential breaches of fiduciary duties by certain directors and officers of Roka Bioscience was announced.
Investors who are current long term investors in Roka Bioscience Inc (NASDAQ:ROKA) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ:ROKA stocks follows a lawsuit filed recently against Roka Bioscience Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:ROKA stocks, concerns whether certain Roka Bioscience officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Roka Bioscience Inc 's initial public offering ("IPO") documents allegedly failed to disclose known trends and uncertainties about the drastic decline in demand for its Atlas instruments that existed at the time of the IPO.
On November 6, 2014 Roka Bioscience Inc reported its third quarter 2014 financial results. Roka Bioscience reports a Net Loss for the third quarter was $9.1 million, or a loss of $(0.64) per share, compared with $9.4 million, or a loss of $(17.00) per share, for the same period in 2013. Additionally, Roka Bioscience Inc reported that there were no new Atlas® instruments placements made during the quarter. Shares of Roka Bioscience Inc (NASDAQ:ROKA) declined to as low as $2.97 per share on November 7, 2014.
On March 6, 2015, NASDAQ:ROKA shares closed at $4.47 per share.
Those who purchased shares of Roka Bioscience Inc (NASDAQ:ROKA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego